Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancy & Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ADGRG3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | ADGRG3 Lentivirus Premade Particles Full-length ORF with native GAIN domain for stable cell lines. HEK293 Expressed (Native Glycosylation). Endotoxin Controlled. |
View ADGRG3 Products |
| Antigen | ADGRG3 NTF (N-Terminal Fragment) Recombinant Protein ECD-Fc Fusion, Sequence Verified, High Purity (>95%). For binding assays. |
View ADGRG3 Products |
| Benchmark Ab | Anti-ADGRG3 Reference Antibody (Rabbit mAb) Recombinant positive control, Sequence Verified. |
View ADGRG3 Products |
| Validator | ADGRG3 siRNA Set For knockdown verification and specificity controls. |
View ADGRG3 Products |
| Related Target A | ADGRG1 (GPR56) Synergistic adhesion GPCR; critical for selectivity counter-screening. |
View ADGRG1 Products |
| Related Target B | CD19 B-cell lineage marker; combination therapy rationale for B-cell malignancies. |
View CD19 Products |
| Related Target C | CD38 Multiple myeloma target; pathway synergy with ADGRG3 in plasma cells. |
View CD38 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation & Autoproteolysis | Full-length Lentivirus for Stable Cell Lines preserving GAIN domain and Stachel sequence integrity; HEK293 expressed for native glycosylation. |
| Adhesion GPCR Subfamily Selectivity (ADGRG1/GPR56 off-target) | ADGRG1 and ADGRG5 ortholog proteins available; Strictly Sequence Verified for counter-screening. |
| B-Cell Specific Signaling Context | Ramos and Raji cell line transduction protocols available; Native B-cell background for calcium flux assays. |
| Lack of Specificity Controls | Validated siRNA included for target knockdown confirmation; Eliminates false positives in binding assays. |
Live ADGRG3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADGRG3 therapeutics is intensifying, with major academic institutions and emerging biotechs shifting focus from traditional GPCR small molecules to targeted biologics. As an adhesion GPCR highly expressed in malignant B cells and plasma cells, ADGRG3 represents a novel axis for multiple myeloma and autoimmune indications where CD20-directed therapies face limitations.
Critical technical barriers remain: the receptor's dependence on autoproteolytic cleavage and mechanical force for activation necessitates cell-based assay systems over purified protein alone. The next wave of R&D is targeting antibody-mediated receptor modulation (blocking or internalizing) and ADC modalities, requiring high-fidelity cell line models that preserve native glycosylation and conformational dynamics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking) | Academic Consortia, Early Biotech | Autoimmune (SLE), B-cell lymphoma | Cell-based binding (Flow Cytometry) using Lentivirus-stable lines; Selectivity vs ADGRG1 |
| ADC | Emerging Programs | Multiple Myeloma | Internalization Assay (requires native conformation cell line); Endotoxin-controlled reagents |
| Small Molecule Allosteric | Discovery Stage | Immunology | Calcium Flux Assay (Gz coupling); Stable cell line with G16 coupling modification |